Arthritis Drug May Help Ease Other Type of Joint Pain

FEBRUARY 01, 2006

According to the results of a study conducted in both the United States and Europe, adalimumab (Humira), a commonly used rheumatoid arthritis drug, also may help to reduce the symptoms of ankylosing spondylitis (AS). The findings were presented at the annual scientific meeting of the American College of Rheumatology in San Diego, Calif.

The study included 315 AS patients who had no success with at least 1 other form of therapy. The patients were randomly assigned either 40 mg of adalimumab or a placebo for 24 weeks. Researchers used 5 assessment methods to measure the patients' clinical responses to the treatment. The goal was a 20% improvement in AS signs and symptoms.

The researchers found that, at 12 and 24 weeks, more than twice as many patients taking the adalimumab reached the 20% symptom-improvement goal, compared with those taking the placebo. Some patients showed improvement as early as 2 weeks into the study.




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.